X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/akeso-presented-promising-results-of-cadonilimab-and-lenvatinib-in-combination-with-tace-in-uhcc-at-2024-asco-gi-302041570.html
https://www.prnewswire.com/news-releases/fostrox--lenvima-shows-further-improved-response-rates-and-time-to-progression-in-advanced-liver-cancer-hcc-at-asco-gi-symposium-302036736.html
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-eisais-cancer-therapy-combo-fails-late-stage-study-2023-12-08/
https://www.fiercepharma.com/pharma/merck-and-eisais-keytruda-lenvima-combo-chalks-another-loss-time-non-small-cell-lung-cancer
https://www.prnewswire.com/news-releases/medivir-reports-promising-interim-data-including-a-first-complete-response-in-phase-1b2a-hcc-study-with-fostrox-in-combination-with-lenvima-301916719.html
https://endpts.com/merck-and-eisai-to-stop-keytruda-plus-lenvima-trial-in-head-and-neck-cancer-after-disappointing-interim-results/
https://www.prnewswire.com/news-releases/promising-tumor-control-for-fostrox-in-combination-with-lenvima-in-ongoing-phase-2a-study-in-hcc-15th-patient-included-301899544.html
https://www.onclive.com/view/long-term-os-data-confirm-pembrolizumab-lenvatinib-as-a-primary-frontline-option-in-advanced-rcc
https://www.indianpharmapost.com/news/shilpa-medicare-launches-lenvatinib-capsules-in-india-under-the-brand-name-lenshil-14340
https://www.prnewswire.com/news-releases/first-patient-dosed-in-the-phase-2a-part-of-medivirs-study-with-fostrox-in-combination-with-lenvima-301771233.html
https://www.prnewswire.com/news-releases/medivir-has-completed-a-successful-pre-ind-meeting-with-the-fda-301700044.html
https://www.prnewswire.com/news-releases/eisai-announces-real-world-evidence-on-the-clinical-effectiveness-of-lenvima-lenvatinib-monotherapy-for-the-treatment-of-patients-with-radioiodine-refractory-differentiated-thyroid-cancer-301655499.html
https://pharmaphorum.com/news/scotland-backs-three-new-uses-for-msds-keytruda/
https://www.pharmatimes.com/news/positive_appraisal_for_eisais_kisplyx_in_combination_with_msds_keytruda_1453573
https://www.fiercepharma.com/pharma/regenerons-libtayo-chemotherapy-combo-may-suffer-lung-cancer-delay-could-war-ukraine-be
https://www.fiercepharma.com/pharma/merck-eisai-s-lenvima-fails-to-improve-keytruda-bladder-cancer-as-key-padcev-combo-readout
https://www.prnewswire.com/news-releases/first-patient-dosed-in-the-miv-818-combination-study-301444123.html
https://www.fiercepharma.com/pharma/merck-eisai-s-007-goes-down-as-keytruda-lenvima-combo-fails-newly-diagnosed-lung-cancer
https://www.pharmaceutical-technology.com/news/ec-approval-merck-endometrial-cancer/
https://www.acnnewswire.com/press-release/english/69568/eisai-to-present-abstracts-on-oncology-products-and-pipeline-at-esmo-virtual-congress-2021
http://www.pharmafile.com/news/579590/msd-announce-new-data-advanced-renal-cell-carcinoma-trial
https://www.prnewswire.com/news-releases/eisai-data-at-asco-2021-highlight-breadth-of-oncology-portfolio-across-various-tumor-types-301292077.html
https://www.biospectrumasia.com/news/97/17869/eisais-anti-cancer-agent-lenvatinib-pembrolizumab-combo-receives-ema-in-japan.html
http://www.acnnewswire.com/press-release/english/65607/eisai:-european-medicines-agency-accepts-the-marketing-authorisation-applications-for-two-additional-indications-of-anti-cancer-agent-lenvatinib-in-co
https://www.biospectrumasia.com/news/97/17869/eisais-anti-cancer-agent-lenvatinib-pembrolizumab-combo-receives-ema-in-japan.html
https://www.businesswire.com/news/home/20210319005069/en/KEYTRUDA%C2%AE-pembrolizumab-Plus-LENVIMA%C2%AE-lenvatinib-Significantly-Improved-Progression-Free-Survival-and-Overall-Survival-Versus-Chemotherapy-in-Patients-With-Advanced-Endometrial-Cancer-Following-Prior-Platinum-Based-Chemotherapy-in-Phase-3-Study
https://www.onclive.com/view/lenvatinib-plus-pembrolizumab-or-everolimus-improves-survival-responses-versus-sunitinib-in-advanced-rcc
https://www.prnewswire.com/news-releases/eisai-to-present-investigational-data-on-lenvima-lenvatinib-based-combination-therapies-in-renal-cell-carcinoma-at-the-2021-genitourinary-cancers-symposium-301215771.html
https://www.prnewswire.com/news-releases/eisai-to-present-data-on-lenvima-lenvatinib-monotherapy-and-in-combination-with-keytruda-pembrolizumab-in-multiple-cancer-types-at-the-2021-gastrointestinal-cancers-symposium-301203639.html
https://www.merck.com/news/keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-demonstrated-statistically-significant-improvement-in-overall-survival-progression-free-survival-and-objective-response-rate/
https://www.prnewswire.com/news-releases/eisai-announces-new-investigational-data-from-study-211-evaluating-the-starting-dose-of-lenvima-lenvatinib-in-differentiated-thyroid-cancer-at-esmo-asia-2020-301178302.html
https://www.pharmacompass.com/pdf/news/moberg-pharma-decides-on-fully-guaranteed-rights-issue-of-approximately-sek-150m-1606298316.pdf
https://www.prnewswire.com/news-releases/eisai-announces-investigational-data-highlighting-lenvima-lenvatinib-based-combination-therapy-in-patients-with-renal-cell-carcinoma-at-ikcs-2020-301167612.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bdr-pharma-launches-generic-cancer-drug-in-india/articleshow/78785817.cms
http://www.pharmafile.com/news/559908/new-lenvimakeytruda-combo-data-range-cancers-presented-esmo-2020
https://www.merck.com/news/mercks-keytruda-pembrolizumab-reduced-the-risk-of-distant-metastasis-or-death-by-40-versus-placebo-as-adjuvant-treatment-in-resected-high-risk-stage-iii-melanoma/
https://www.merck.com/news/new-scientific-data-at-the-esmo-virtual-congress-2020-reflect-mercks-commitment-to-advancing-cancer-research-and-care/
https://eisai.mediaroom.com/2020-08-11-Eisai-Announces-Topline-Results-from-Study-211-Supporting-24-mg-as-the-Appropriate-Starting-Dose-for-LENVIMA-R-lenvatinib-in-Patients-with-Differentiated-Thyroid-Cancer
https://www.prnewswire.com/news-releases/eisai-to-present-latest-data-from-oncology-pipeline-at-asco-2020-including-keytruda-pembrolizumab-plus-lenvima-lenvatinib-investigational-combination-therapy-and-halaven-eribulin-mesylate-301058986.html
Market Place
Share 
